CO6382185A2 - Compuestos nucleosidos antivirales - Google Patents

Compuestos nucleosidos antivirales

Info

Publication number
CO6382185A2
CO6382185A2 CO10057513A CO10057513A CO6382185A2 CO 6382185 A2 CO6382185 A2 CO 6382185A2 CO 10057513 A CO10057513 A CO 10057513A CO 10057513 A CO10057513 A CO 10057513A CO 6382185 A2 CO6382185 A2 CO 6382185A2
Authority
CO
Colombia
Prior art keywords
compounds
nucleosid
antiviral
treatment
hepatitis
Prior art date
Application number
CO10057513A
Other languages
English (en)
Inventor
Brett C Bookser
Scott J Hecker
Raja K Reddy
David Bernard Smith
Zhili Sun
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679083&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6382185(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of CO6382185A2 publication Critical patent/CO6382185A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compuestos que poseen la fórmula I o II en la que R1, R2, B, y V son tal como se ha definido aquí son inhibidores de la polimerasa NS5b del virus de la hepatitis C. También se describen composiciones y métodos para el tratamiento de una infección por VHC y que inhiben la replicación de VHC.
CO10057513A 2007-11-29 2010-05-13 Compuestos nucleosidos antivirales CO6382185A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99116307P 2007-11-29 2007-11-29
US8454408P 2008-07-29 2008-07-29

Publications (1)

Publication Number Publication Date
CO6382185A2 true CO6382185A2 (es) 2012-02-15

Family

ID=40679083

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10057513A CO6382185A2 (es) 2007-11-29 2010-05-13 Compuestos nucleosidos antivirales

Country Status (20)

Country Link
US (2) US8063025B2 (es)
EP (1) EP2227481A4 (es)
JP (1) JP2011505351A (es)
KR (1) KR20100103793A (es)
CN (1) CN102164939A (es)
AR (1) AR069740A1 (es)
AU (1) AU2008331158A1 (es)
BR (1) BRPI0819797A2 (es)
CA (1) CA2706432A1 (es)
CL (1) CL2008003511A1 (es)
CO (1) CO6382185A2 (es)
CR (1) CR11453A (es)
EC (1) ECSP10010210A (es)
IL (1) IL205625A0 (es)
MA (1) MA31864B1 (es)
MX (1) MX2010005885A (es)
RU (1) RU2010126050A (es)
TW (1) TW200936146A (es)
WO (1) WO2009069095A2 (es)
ZA (1) ZA201003438B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0819831A2 (pt) 2007-11-29 2019-09-24 Boehringer Ingelheim Int derivados de amidas de áciodo 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-carboxílico
CN102725303B (zh) * 2010-01-28 2015-05-27 里博科学有限责任公司 作为抗hcv化合物的4’-叠氮基-核苷
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
EP2776438A4 (en) * 2011-11-10 2015-04-29 Inhibitex Inc SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
US9676809B2 (en) 2013-11-22 2017-06-13 Ligand Pharmaceuticals Incorporated Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections
CN103848877B (zh) * 2013-12-16 2016-08-24 安徽贝克联合制药有限公司 核苷环磷酸酯化合物及其制备方法和其应用
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
EP3331894B1 (en) 2015-08-05 2021-02-17 Metro International Biotech, LLC Nicotinamide mononucleotide derivatives and their uses
WO2018129040A1 (en) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
CN108727450B (zh) * 2017-04-18 2024-02-20 浙江柏拉阿图医药科技有限公司 肝递送抗丙肝前体药物核苷环磷酸酯化合物及应用
CN109956975B (zh) * 2017-12-22 2020-11-06 浙江柏拉阿图医药科技有限公司 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用
CN109956986B (zh) * 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
CN109956985A (zh) * 2017-12-22 2019-07-02 浙江柏拉阿图医药科技有限公司 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CN111434671B (zh) * 2019-01-11 2023-07-11 凯思凯迪（上海）医药科技有限公司 肝脏特异性ampk激动剂及其制法和应用
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767599B2 (en) * 1998-03-06 2003-11-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
CA2503730C (en) * 2002-10-31 2011-10-18 Metabasis Therapeutics, Inc. Cytarabine monophosphate prodrugs
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2005009418A2 (en) * 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
EP1781101A2 (en) 2004-07-29 2007-05-09 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
JP4954573B2 (ja) * 2006-02-28 2012-06-20 オリンパス株式会社 内視鏡システム

Also Published As

Publication number Publication date
AR069740A1 (es) 2010-02-17
US8063025B2 (en) 2011-11-22
CN102164939A (zh) 2011-08-24
CL2008003511A1 (es) 2010-02-19
MA31864B1 (fr) 2010-11-01
MX2010005885A (es) 2010-11-24
ZA201003438B (en) 2011-04-28
US20120039845A1 (en) 2012-02-16
TW200936146A (en) 2009-09-01
RU2010126050A (ru) 2012-01-10
BRPI0819797A2 (pt) 2019-09-24
KR20100103793A (ko) 2010-09-28
EP2227481A4 (en) 2011-03-09
WO2009069095A2 (en) 2009-06-04
JP2011505351A (ja) 2011-02-24
IL205625A0 (en) 2010-11-30
EP2227481A2 (en) 2010-09-15
WO2009069095A3 (en) 2009-12-23
AU2008331158A1 (en) 2009-06-04
CR11453A (es) 2010-10-27
ECSP10010210A (es) 2010-08-31
CA2706432A1 (en) 2009-06-04
US20090209481A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
ECSP10010210A (es) Compuestos nucleósidos antivirales
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
ECSP11011513A (es) Compuestos heterocíclicos antivirales
ECSP12012282A (es) Fosforamidatos de nucleósido
CR10136A (es) Nucleósidos antivirales
CY1118111T1 (el) Υποκατεστημενα αλειφανια, κυκλοφανια, ετεραφανια, ετεροφανια, ετερο-ετεραφανια και μεταλλοκενια που ειναι χρησιμα για τη θεραπευτικη αντιμετωπιση hcv λοιμωξεων
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
ECSP10010618A (es) Análogos carba - nucleósidos para tratamiento antiviral
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
CO6430431A2 (es) Inhibidores del virus de la hepatitis c
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
CL2011000145A1 (es) Compuesto macrociclico derivado de quinoxalina y sus sales; inhibidor de la proteasa ns3 del virus de la hepatitis c(hcv); composicion farmaceutica que lo comprende; y uso en la prevencion o el tratamiento de una infeccion por hcv.
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
MX2012003170A (es) Compuestos heterociclicos antivirales.
UY28581A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
GT200600317A (es) Inhibidores de la proteasa ns3 del vhc
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados

Legal Events

Date Code Title Description
FA Application withdrawn